Background/Objectives: Incidence of malnutrition varies greatly among gastrointestinal (GI) cancer patients and has a major impact on prognosis. We performed a meta-analysis to identify risk factors for malnutrition risk, malnutrition diagnosis, and cachexia in patients with GI cancer. Methods: A systematic search was performed on 31 October 2025 on the PubMed (Medline), Embase, and Cochrane Library databases. Eligible studies reported on risk factors for malnutrition risk, malnutrition diagnosis, malnutrition-related complication risk and cachexia in adult patients with GI cancer. Articles on neuroendocrine tumours, primary cancer outside the GI tract, and the paediatric population were excluded. The random-effects model yielded the pooled odds ratios (ORs) and 95% confidence intervals (CIs) for the investigated risk factors. Results: A total of 37,624 records were identified. Data from 262,525 patients from 578 articles were included in the analysis. Older age (≥65) was associated with higher odds for malnutrition risk across all GI cancers. In gastric cancer, males had a lower odds for malnutrition risk (OR 0.84; 95% CI 0.75–0.95); however, the sex difference across other cancer types was heterogeneous, and mostly not significant. Tumour location influenced the odds for malnutrition-related complication risk in pancreatic ductal adenocarcinoma (head vs. body/tail—OR 1.48; 95% CI 0.98–2.23) and colorectal cancer (colon vs. rectal—OR 1.39; 95% CI 1.07–1.81; right-sided vs. left-sided—OR 1.54; 95% CI 1.34–1.77). Increased C-reactive protein alone indicated higher odds for malnutrition risk at baseline. Conclusions: Inflammatory biomarkers and tumour characteristics may indicate malnutrition risk in GI cancer at baseline. There is a great need for standardised and harmonised approaches in nutritional status assessment in GI cancer.

INTRODUCTION: The magnitude and modifiers of the association between acute pancreatitis (AP) and pancreatic cancer (PC) are unclear. This systematic review and meta-analysis aimed to quantify the occurrence of PC in AP, the association of PC after AP, and the impact of specific risk factors on PC diagnosis. METHODS: The systematic search was conducted in PubMed, EMBASE, and Central Register of Controlled Trial from inception until July 14, 2025 (PROSPERO: CRD42023470350). Eligible studies included adult populations reporting on the association between AP and PC. Primary outcomes included prevalence, incidence, and diagnosis of PC in individuals with AP, including subset analyses of specific clinical and demographic factors. Meta-analyses were performed using random-effects models to calculate pooled outcome measures and corresponding 95% confidence intervals (CI). RESULTS: A total of 61 studies were included. The prevalence of PC among AP patients was 2% (CI: 2%–4%). The time-dependent analysis revealed an increased hazard of PC in AP vs no AP: 60 months (HR: 1.71, CI: 1.22–2.40). AP patients with subsequently diagnosed chronic pancreatitis (OR: 3.71, CI: 2.00–6.90), new-onset diabetes mellitus (OR: 2.22, CI: 1.02–4.84), idiopathic AP (OR: 2.97, CI: 1.44–6.13), and older than 50 years (OR: 4.04, CI: 2.73–5.97) showed significantly increased odds of having PC. We found no evidence for increased odds for PC with AP severity, smoking, and alcoholic and gallstone etiologies. DISCUSSION: Patients with AP have a higher likelihood of PC diagnosis, especially within the first 2 years. Although the association decreases with time, it remains significant long term. Newly diagnosed chronic pancreatitis, new-onset diabetes mellitus, idiopathic AP may further elevate the likelihood of PC diagnosis. PC diagnosed after AP tends to occur at a younger age, more often at an earlier stage, typically in the pancreatic head.

Background/Objectives: Cardiovascular diseases (CVDs) frequently limit the feasibility and effectiveness of cancer treatment. However, CVD burden has not been comprehensively described in pancreatic cancer. In our systematic review and meta-analysis, we evaluated the prevalence and incidence of CVDs in pancreatic ductal adenocarcinoma (PDAC). Methods: We conducted the systematic search in PubMed, EMBASE, and CENTRAL on 5 February 2024. Studies reporting the prevalence or incidence of CVDs in PDAC were included. Subgroup analyses were performed based on cancer stage and treatment type. Pooled proportions with the 95% confidence interval (CI) were calculated using a random-effects model. (PROSPERO: CRD42023482295). Results: We included 197 articles. At PDAC diagnosis, non-thrombotic cardiovascular diseases (NT-CVDs) were as prevalent as in the general population: hypertension in 33% (CI: 27–40%), ischemic heart disease in 6% (CI: 3–12%), and heart failure, arrhythmia, and stroke each in 2–3%. Their incidence during treatment remained low (1–10%). Thrombotic events, excluding pulmonary embolism, were present in 11% (CI: 7–15%) at diagnosis, with an incidence of 8–10% regardless of stage or treatment. Pulmonary embolism affected 3% at diagnosis and occurred at a similar rate during treatment. Conclusions: Thromboembolic events are common in PDAC and occur both at diagnosis and during follow-up. Their incidence remains stable across treatment modalities and disease stages, suggesting that the tumor itself is the primary driver of thrombotic risk. The prevalence of NT-CVDs in PDAC is comparable to that in the general population and shows minimal variation across cancer stages or treatment modalities.